Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025
Akero Therapeutics (NASDAQ: AKRO) presented new analyses of their Phase 2b HARMONY...
Akero Therapeutics (NASDAQ: AKRO) presented new analyses of their Phase 2b HARMONY...